Azithromycin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Azithromycin
- Pharmacist Assessment Report
- Azithromycin: macrolide antibiotic → polyclonal hyperviscosity syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Azithromycin: macrolide antibiotic → polyclonal hyperviscosity syndrome
One-Sentence Summary
Azithromycin is a macrolide antibiotic marketed in Canada under multiple single-ingredient licences. The TxGNN model predicts it may be relevant to polyclonal hyperviscosity syndrome, but this is a model prediction only: 0 clinical trials and 0 publications were found for this disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | polyclonal hyperviscosity syndrome |
| TxGNN Prediction Score | 0.9981 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 19; dormant: 1) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Azithromycin is a macrolide antibiotic with antibacterial activity and reported immunomodulatory properties.
Polyclonal hyperviscosity syndrome is a condition of increased blood viscosity caused by elevated immunoglobulins from a polyclonal gammopathy. No plausible mechanistic link between azithromycin and this condition is established in the data compiled for this report. The high score (0.9981) is a model output and is not supported by any trial or publication. The prediction should be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Azithromycin is marketed in Canada with 20 valid single-ingredient licences, and the licence list may be partial. Selected products:
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02452308 | JAMP-AZITHROMYCIN | Not recorded | Not recorded |
| 02523825 | AZITHROMYCIN FOR INJECTION | Not recorded | Not recorded |
| 02415542 | APO-AZITHROMYCIN Z | Not recorded | Not recorded |
| 02267845 | TEVA-AZITHROMYCIN | Not recorded | Not recorded |
| 02265826 | SANDOZ AZITHROMYCIN | Not recorded | Not recorded |
Safety Considerations
- Drug Interactions: Interaction screening completed with 100 interacting drugs recorded. Major-level interactions include cisapride and dolasetron. Moderate-level interactions include famotidine, loperamide, clarithromycin, levofloxacin, granisetron, aluminum hydroxide and magnesium-containing antacids, and several laxatives. Minor-level interactions include amoxicillin and metronidazole.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. No clinical trial or publication studies azithromycin in polyclonal hyperviscosity syndrome, and no mechanistic link is established.
To proceed, the following is needed:
- Mechanism of action data and a credible biological rationale linking azithromycin to hyperviscosity from polyclonal gammopathy
- Preclinical or clinical studies that directly address this disease
- Review of the Canadian package insert for warnings and contraindications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.